//fpnotebook.com/
Efavirenz
Aka: Efavirenz, Sustiva, EFV
- See Also
- Anti-Retroviral Therapy
- Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- Class
- Anti-retroviral agent
- Non-Nucleoside Reverse Transcriptase Inhibitor
- First generation agent
- Indications: HIV and AIDS
- Most commonly used NNRTI in 2011 and available in combination (Atripla)
- Dosing
- Adult
- Efavirenz 600 mg qhs
- Child
- Weight 10-14 kg: 200 mg qhs
- Weight 15-19 kg: 250 mg qhs
- Weight 20-24 kg: 300 mg qhs
- Weight 25-32 kg: 350 mg qhs
- Weight 32-40 kg: 400 mg qhs
- Adverse Effects
- General: CNS effects
- Onset 1-3 hours after dose
- Symptoms abate over 1-2 weeks
- CNS adverse effects (affects 50% at 1 month, 23% at 3 months, baseline at 6 months)
- Dizziness
- Headache
- Insomnia
- Difficulty concentrating
- Vivid dreams
- Nightmares
- Hallucinations
- Pregnancy
- Potentially Teratogenic
-
Drug Interactions
- Take on empty Stomache at bedtime
- Induces CYP3A4 enzyme
- Decreases serum levels of some Protease Inhibitors
- Avoid concurrent use of Saquinavir
- Raise dose of Indinavir to 1000 mg PO q8h
- Decreases some Macrolide levels
- Decreases Clarithromycin level
- Azithromycin not effected
- Labs
- Causes False Positive drug screen for cannabinoids, Benzodiazepines
- Reference
- (1998) Med Lett Drugs Ther 40(1041):115 [PubMed]
- (2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]